Biomea Fusion (BMEA) announced that it will feature two oral presentations, one poster presentation, and chair a symposium at the 18th ...

Presentation to highlight new clinical data from COVALENT-111, including c-peptide data ...

GAITHERSBURG, Md., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical ...

While one study found lower rates of preterm birth alongside higher rates of hypertensive disorders, another found fewer ...

GLP-1 Receptor Agonist Market. The global GLP-1 receptor agonist market is on the verge of unprecedented growth, fueled by ...

Risk of suicidality wasn't higher for type 2 diabetes patients starting on GLP-1 receptor agonists than for those on two other popular classes of diabetes drugs, a U.K. cohort study found. In fully ...

On his Instagram profile, the “Queer Eye” star Jonathan Van Ness detailed that he lost 30 kg with GLP-1 weight-loss ...

“The thing most amazing about them is how these drugs suddenly alter the dopamine-related reward pathway in the brain making us less of a slave to cravings. Today, 73% of Americans are obese or ...

A study comparing GLP-1 users to others on antidiabetic drugs showed no added risk once confounders were accounted for.

The Company granted Mr. Gengos a new hire option to purchase 750,000 shares of Terns common stock. The option has a 10-year term and an exercise price per share equal to $3.73, which was the closing ...

Researchers investigating the role of the protein CD44 in obesity and metabolic health found that CD44-deficient mice stayed ...

For individuals with type 2 diabetes (T2D), semaglutide is associated with a modestly increased risk for nonarterit ...